CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
利用 T 细胞治疗多发性骨髓瘤：新治疗范式的黎明
英文原题：Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.
查看英文原题
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤是一种无法治愈的血液系统恶性肿瘤。典型病程是患者先对治疗产生应答，随后最终出现耐药。只要患者仍有新的治疗线可用，缓解和复发就会继续交替发生。面对这一现实，研究者开发了多种新型免疫疗法。其中许多药物利用患者自身T细胞的细胞毒能力，重新定向T细胞攻击原本可逃避免疫攻击的骨髓瘤细胞。CAR-T 细胞疗法和双特异性抗体等方法已在骨髓瘤患者临床试验中显示出令人瞩目的疗效。本综述考察多种利用T细胞治疗多发性骨髓瘤的方法，并分析这些令人振奋新策略的获益与风险。
展开英文摘要原文
Multiple myeloma is an incurable hematologic malignancy. The typical disease course for myeloma patients is characterized by initial response to treatment followed by eventual development of resistance. Subsequent cycles of remission and relapse proceed as long as patients have new lines of therapy available to them. This reality has prompted development of many novel immunotherapeutics.
Many of these drugs exploit the cytotoxic capabilities of the patients' own T cells, effectively redirecting them to myeloma cells that are otherwise evading immune attack. Approaches including CAR T cell therapy and bispecific antibodies have displayed impressive efficacy in clinical trials for myeloma patients. This review examines the different approaches that utilize T cells in multiple myeloma therapy and investigates the benefits and risks of these exciting new strategies.
论文信息
- 作者
- Keller AL、Sherbenou DW、Forsberg PA、Mark TM
- 单位
- Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.United States
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2022
- 原文标识
- PubMed 35814431 · DOI 10.3389/fonc.2022.925818
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →